

# LAPS - Female patients with breast cancer treated with lapatinib in the context of an expanded access program (ATU): description of the care trajectory and clinical course

Head :Leclerc-Zwirn Christel, Laboratoire GSK

Last update : 01/01/2020 | Version : 1 | ID : 155

## General

### Identification

Detailed name Female patients with breast cancer treated with lapatinib in the context of an expanded access program (ATU): description of the care trajectory and clinical course

Sign or acronym LAPS

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL : 1213267

### General Aspects

Medical area Cancer research

Others (details) Breast cancer

Keywords HER2+, Tyverb

### Scientific investigator(s) (Contact)

Name of the director Leclerc-Zwirn

Surname Christel

Phone +33 (0)1 39 17 86 96

Email christel.c.leclerc-zwirn@gsk.com

Unit Laboratoire GSK

### Collaborations

### Funding

Funding status Private

Details	GSK laboratory
<b>Governance of the database</b>	
Sponsor(s) or organisation(s) responsible	Laboratoire GSK
Organisation status	Private
<b>Additional contact</b>	
<b>Main features</b>	
<b>Type of database</b>	
Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	<p>One hundred centers have filed at least one TUA request as of July 31, 2007 (about 3 months before the initiation of the study): about thirty of these are centers of substantial size (at least 5 patients, 10 patients on the average), the other 70 are small centers (less than 5 patients, 4 patients on the average).</p> <p>The study will be proposed to 80% of the centers in each stratum (center size). The random drawing will make it possible, as such, to retain 56 small centers and 25 large centers. Based on an estimated response rate of 70%, 40 small centers and 18 large centers will in the end participate in the study:</p> <p>Random drawing and number of patients expected: Based on the eligibility criteria retained, an additional CRF will have to be completed for all of the patients of a center. No random drawing will be carried out at this level.</p> <p>Approximately 570 patients received a treatment via lapatinib over the period of the study retained. Based on participation of 58 of the 81 centers that had requested a TUA, to which this study will be</p>

proposed, 330 completed dossiers can be expected.

## Database objective

**Main objective** Describe the care pathways of patients with breast cancer who have received and/or are receiving treatment with lapatinib under Temporary Use Authorization (TUA)

**Inclusion criteria** Patient who has received lapatinib for the treatment of breast cancer within the framework of a TUA between January 1, 2007 and 3 months prior to the beginning of the study

## Population type

**Age** Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)  
Elderly (65 to 79 years)  
Great age (80 years and more)

**Population covered** Sick population

**Gender** Woman

**Geography area** National

**Detail of the geography area** France

## Data collection

### Dates

**Date of first collection (YYYY or MM/YYYY)** 2008

**Date of last collection (YYYY or MM/YYYY)** 2010

### Size of the database

**Size of the database (number of individuals)** < 500 individuals

**Details of the number of individuals** 198

## Data

**Database activity** Data collection completed

Type of data collected	Clinical data
Clinical data (detail)	Direct physical measures Medical registration
Presence of a biobank	No
Health parameters studied	Health event/morbidity Health event/mortality Health care consumption and services
Care consumption (detail)	Hospitalization Medical/paramedical consultation Medicines consumption
<b>Procedures</b>	
Data collection method	The investigating centers (prescribing doctor) that have accepted to carry out the study will receive a CRF for all of their patients eligible for the study: patient number, sex, age and treatment start date will be pre-completed in order to identify the patients. Prescribing doctors will complete the CRF using the medical doctor, based on the information available, and will return it to the logistics center
Participant monitoring	No
Links to administrative sources	No
<b>Promotion and access</b>	
<b>Promotion</b>	
<b>Access</b>	
Terms of data access (charter for data provision, format of data, availability delay)	Abstract (ISPOR 2009) Publication in progress
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only